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Summary We determined the prevalence of antineutrophil cytoplasmic antibodies (ANCAs) in
patients with systemic lupus erythematosus (SLE) and evaluated the correlation
between ANCA positivity and clinical features. Forty-one patients with SLE and two
control groups were examined. One of the control groups consisted of 15 patients with
systemic vasculitis, and the other of 12 healthy blood donors. A quantitative enzyme-
linked immunosorbent assay technique was used to measure the serum cytoplasmic
ANCA (cANCA) and perinuclear ANCA (pANCA) levels. cANCA positivity was found in
three patient samples, and pANCA positivity in 10 SLE patients. The occurrence and
titres of both ANCA types in SLE patients were similar to those in healthy controls and
significantly lower than those in patients with systemic vasculitis. The clinical picture
and antibody profile were similar in ANCA-positive and ANCA-negative SLE patients.
We conclude that measurement of ANCAs does not provide any additional diagnostic
or prognostic data in SLE.
Report
Antineutrophil cytoplasmic antibodies (ANCAs) are
directed against various components of the cytoplasm
of the neutrophil granulocyte.1 By means of indirect
immunofluorescence examination, two types of ANCA
can be distinguished, either a cytoplasmic (cANCA) or a
perinuclear (pANCA) staining pattern being observed.
ANCAs are often detected in certain types of systemic
vasculitides2 but they can also be found in other
inflammatory diseases; this has led to the introduction
of the term ÔANCA-associated diseaseÕ.
In the present study, we examined the prevalence of
ANCA among systemic lupus erythematosus (SLE)
patients and examined whether there is a correlation
between ANCA positivity and various clinical features of
SLE.
Forty-one patients with SLE (38 females and three
males) were examined (age 19–70 years, mean 42.3).
Nine patients had clinical signs of SLE-associated
vasculitis: panniculitis (two patients) or skin vasculitis
(seven patients). One of the control groups consisted of
15 patients with various types of systemic vasculitides
(age 22–78 years, mean 49.4). The other control group
comprised 12 healthy blood donors (age 23–46 years,
mean 33.0).
ANCAs were measured by an enzyme-linked immu-
nosorbent assay (ELISA; Shield Diagnostics, Dundee,
UK). The antigens were proteinase-3 (PR-3) for cANCA
and myeloperoxidase (MPO) for pANCA. The normal
levels were < 2 U ⁄ L for cANCA and < 7 U ⁄ L for
pANCA. Other autoantibodies were also investigated:
antinuclear antibody by indirect immunofluorescence;
anti-double-stranded DNA (anti-dsDNA), anti-SSA, anti-
SSB, anti-Sm, anti-U1-RNP and anticardiolipin by
ELISA; lupus anticoagulant by activated partial
thromboplastin time. Statistical analysis was performed
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with the Fisher exact test (to compare the prevalences of
ANCA positivity in the three groups) and an analysis of
variance test with the least significant difference method
(for average ANCA titres).
Elevated levels of cANCA were detected in three SLE
patients and of pANCA in 10 SLE patients (Fig 1a, b). In
one patient, both the cANCA and the pANCA concen-
trations were higher than normal. In all the positive SLE
patients, cANCA levels were in the low positive range
(2–6 U ⁄ L), similarly to those of pANCA (7–25 U ⁄ L). In
the control patients with systemic vasculitides, elevated
cANCA levels were significantly more frequent than in
the SLE group (7 ⁄ 15 vs 3 ⁄ 41; P  0.002), while the
prevalence of pANCA did not differ in the two groups
(5 ⁄ 15 vs 10 ⁄ 41; P  0.51). The average ANCA levels
were significantly higher in the vasculitis group than in
the SLE group (cANCA: 10.5 U ⁄ L vs 1.0 U ⁄ l, P  0.01;
pANCA: 15.5 U ⁄ L vs 5.1 U ⁄ l, P  0.01). One healthy
control exhibited antibody positivity against PR-3, and a
further one did so against MPO (Fig 1a, b). The mean
antibody titres (cANCA, 0.7 U ⁄ l; pANCA, 3.7 U ⁄ L) and
the prevalences of both ANCA types in the healthy
control group were similar to those in the SLE group.
However, it is noteworthy that pANCA positivity
occurred almost three times more frequently in the
SLE group than in the normal individuals, although the
difference was statistically not significant (24.4% vs
8.3%, P  0.42).
As concerns the organ manifestations, the autoanti-
body profile, and the age of the patients at the time of
diagnosis, there were no statistically significant differ-
ences between the ANCA-positive and ANCA-negative
patients (Table 1). The SLE disease activity index was
also similar in ANCA-positive (12.8) and ANCA-nega-
tive (10.2) patients.
The published results concerning the value of
ANCA in SLE are controversial. While some authors
have found high anti-PR3 titres in 17.4%3 and
13.6%4 of their SLE patients, others have described
the complete absence of cANCA in SLE.5, 6 The
reported frequencies of anti-MPO antibodies are
between 0% and 21%.5, 7 We detected low positive
levels of cANCA in three SLE patients, and of pANCA
in 10 of the 41 SLE patients. The prevalence of the
latter antibody is the highest observed to date, but
nevertheless we did not find any statistically signifi-
cant differences in the prevalence or the titres of the
two ANCA types between SLE patients and healthy
controls. Our results are also consistent with those of
previous studies5 in that ANCA-positive SLE patients
usually exhibit low titres of this antibody.
Some authors have observed more frequent occur-
rences of serositis, arthritis or neurological involvement
in ANCA-positive patients.8, 9 ANCA positivity can also
be present in primary Sjo¨gren’s syndrome, reportedly in
association with vascular manifestations of the dis-
ease.10 We therefore examined whether there is a
correlation between ANCA positivity and the presence
of various clinical manifestations of SLE (including
vasculitis), but we failed to detect any such relationship.
Previous reports suggested a correlation between ANCA
positivity and anti-dsDNA positivity.8, 9 However, we
did not find a significant association between the
presence of ANCAs and anti-dsDNA, anti-SSA, anti-
SSB, anti-Sm, anti-U1-RNP and anticardiolipin auto-
antibodies or lupus anticoagulant.
We conclude that, on the basis of ANCA positivity, no
specific SLE subgroups could be identified. Although
ANCA (especially pANCA) can occur in low titres in a
minority of SLE patients, it is our experience that
routine examination for ANCA in SLE patients is
unnecessary, as the results do not furnish any addi-
tional data of value concerning the diagnosis or
prognosis.
Figure 1 (a) cANCA levels and (b) pANCA levels in the patients
with SLE, in the control patients with vasculitis and in the healthy
control group. cANCA levels: < 2 U ⁄ L, normal; 2–6 U ⁄ L, mildly
elevated; > 6 U ⁄ L, highly elevated. pANCA levels: < 7 U ⁄ L,
normal; 7–25 U ⁄ L, mildly elevated; > 25 U ⁄ L, highly elevated.
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Table 1 A comparison of organ involvements and serological changes in patients with SLE in relation to the presence of ANCAs.
Symptoms ⁄ Autoantibody positivity
SLE
(n  41)
cANCA+
(n  3)
pANCA+
(n  10)
ANCA)
(n  29)
Butterfly erythema 3 0 0 3
Photosensitivity 7 0 2 5
Discoid lupus erythematosus 2 0 0 2
Oral ulcer 1 0 0 1
Anaemia ⁄ leukopenia 16 ⁄ 11 2 ⁄ 1 3 ⁄ 2 11 ⁄ 8
Arthritis 23 1 4 18
Nephritis 12 1 3 8
Serositis 10 1 2 7
Cerebral involvement 2 0 1 1
Skin vasculitis 9 0 0 9
a-DNA 25 ⁄ 40 2 ⁄ 3 7 ⁄ 10 16 ⁄ 28
a-SSA 7 ⁄ 40 1 ⁄ 3 0 ⁄ 10 6 ⁄ 28
a-SSB 7 ⁄ 40 0 ⁄ 3 1 ⁄ 10 6 ⁄ 28
a-Sm 2 ⁄ 40 0 ⁄ 3 1 ⁄ 10 1 ⁄ 28
a-RNP 7 ⁄ 40 1 ⁄ 3 1 ⁄ 10 5 ⁄ 28
LAC 8 ⁄ 26 0 ⁄ 1 2 ⁄ 5 6 ⁄ 20
aCL 16 ⁄ 34 2 ⁄ 2 4 ⁄ 6 10 ⁄ 26
One patient was positive for both cANCA and pANCA.
The numbers of affected patients are included.
No significant differences were observed between the occurrences in the ANCA-negative and ANCA-positive groups.
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